Skip to main content
Erschienen in: Medical Oncology 7/2016

01.07.2016 | Original Paper

ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women

verfasst von: S. Zouine, F. Marnissi, N. Otmani, M. Bennani Othmani, M. El Wafi, K. Kojok, Y. Zaid, N. Tahiri Jouti, N. Habti

Erschienen in: Medical Oncology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

The association between blood groups ABO and different types of diseases was established in several previous studies. Our aim was to seek the possible association between the ABO blood group and breast cancer-associated prognostic factors. The Chi-squared analytic test was used to compare phenotypic ABO distribution among Moroccan blood donors and 442 cases of women suffering from breast carcinoma with archived files in Maternity Ward of University Hospital C.H.U Ibn Rochd between 2008 and 2011. High incidence of breast carcinoma was observed in blood type B patients (p < 0.05). Blood type B was associated with breast carcinomas overexpressing human epidermal growth factor receptor HER2 (p < 0.05) and high risk of cancer at age over 70 years (p < 0.001). Blood type A was associated with high risk of cancer among women younger than 35 years old. Blood type A and AB were associated with high incidence of lymph node metastasis (p < 0.05). Multivariate analysis has shown correlation between O blood type and estrogen receptor-positive tumor. Patients with blood group A, B, and AB were more likely to develop aggressive breast carcinoma. Further follow-up studies are necessary to clarify the role of ABH antigens in the progression of breast carcinoma.
Literatur
1.
Zurück zum Zitat Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 1998;38(10):975–88.CrossRefPubMed Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion. 1998;38(10):975–88.CrossRefPubMed
2.
Zurück zum Zitat Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS. 2000;108(1):1–28.CrossRefPubMed Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS. 2000;108(1):1–28.CrossRefPubMed
3.
Zurück zum Zitat Yamamoto F, et al. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229–33.CrossRefPubMed Yamamoto F, et al. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229–33.CrossRefPubMed
4.
Zurück zum Zitat Yamamoto F, et al. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1—2Gal alpha 1—3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem. 1990;265(2):1146–51.PubMed Yamamoto F, et al. Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1—2Gal alpha 1—3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem. 1990;265(2):1146–51.PubMed
5.
Zurück zum Zitat Simoneau M, et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000;19(54):6317–23.CrossRefPubMed Simoneau M, et al. Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest. Oncogene. 2000;19(54):6317–23.CrossRefPubMed
6.
7.
Zurück zum Zitat Rakosy Z, et al. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;182(2):116–21.CrossRefPubMed Rakosy Z, et al. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2008;182(2):116–21.CrossRefPubMed
8.
9.
Zurück zum Zitat Costantini M, et al. Role of blood groups as prognostic factors in primary breast cancer. Oncology. 1990;47(4):308–12.CrossRefPubMed Costantini M, et al. Role of blood groups as prognostic factors in primary breast cancer. Oncology. 1990;47(4):308–12.CrossRefPubMed
10.
Zurück zum Zitat Mourali N, et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46(12):2741–6.CrossRefPubMed Mourali N, et al. Epidemiologic features of rapidly progressing breast cancer in Tunisia. Cancer. 1980;46(12):2741–6.CrossRefPubMed
11.
Zurück zum Zitat Habti N, Nourichafi N, Benchemsi N. ABO polymorphism in blood donors in Morocco. Transfus Clin Biol. 2004;11(2):95–7.CrossRefPubMed Habti N, Nourichafi N, Benchemsi N. ABO polymorphism in blood donors in Morocco. Transfus Clin Biol. 2004;11(2):95–7.CrossRefPubMed
13.
Zurück zum Zitat Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.CrossRefPubMed Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.CrossRefPubMed
14.
Zurück zum Zitat Annese V, et al. ABO blood groups and cancer of the pancreas. Int J Pancreatol. 1990;6(2):81–8.PubMed Annese V, et al. ABO blood groups and cancer of the pancreas. Int J Pancreatol. 1990;6(2):81–8.PubMed
15.
Zurück zum Zitat Su M, et al. Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaoshan inhabitants of China. World J Gastroenterol. 2001;7(5):657–61.PubMedPubMedCentral Su M, et al. Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaoshan inhabitants of China. World J Gastroenterol. 2001;7(5):657–61.PubMedPubMedCentral
17.
Zurück zum Zitat Aird I, Lee DR, Roberts JA. ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J. 1960;1(5180):1163–6.CrossRefPubMedPubMedCentral Aird I, Lee DR, Roberts JA. ABO blood groups and cancer of oesophagus, cancer of pancreas, and pituitary adenoma. Br Med J. 1960;1(5180):1163–6.CrossRefPubMedPubMedCentral
18.
19.
Zurück zum Zitat Pandey M, Gautam A, Shukla VK. ABO and Rh blood groups in patients with cholelithiasis and carcinoma of the gall bladder. BMJ. 1995;310(6995):1639.CrossRefPubMedPubMedCentral Pandey M, Gautam A, Shukla VK. ABO and Rh blood groups in patients with cholelithiasis and carcinoma of the gall bladder. BMJ. 1995;310(6995):1639.CrossRefPubMedPubMedCentral
20.
21.
Zurück zum Zitat Ben Q, et al. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case–control study. Int J Cancer. 2011;128(5):1179–86.CrossRefPubMed Ben Q, et al. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case–control study. Int J Cancer. 2011;128(5):1179–86.CrossRefPubMed
22.
Zurück zum Zitat Yuzhalin AE, Kutikhin AG. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev. 2012;13(10):5091–6.CrossRefPubMed Yuzhalin AE, Kutikhin AG. ABO and Rh blood groups in relation to ovarian, endometrial and cervical cancer risk among the population of South-East Siberia. Asian Pac J Cancer Prev. 2012;13(10):5091–6.CrossRefPubMed
24.
Zurück zum Zitat Poole EM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23(11):1805–10.CrossRefPubMedPubMedCentral Poole EM, et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control. 2012;23(11):1805–10.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Wang DS, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 2012;131(2):461–8.CrossRefPubMed Wang DS, et al. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 2012;131(2):461–8.CrossRefPubMed
26.
27.
Zurück zum Zitat Woo SM, et al. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case–control study. J Korean Med Sci. 2013;28(2):247–51.CrossRefPubMedPubMedCentral Woo SM, et al. Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case–control study. J Korean Med Sci. 2013;28(2):247–51.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Hsiao LT, et al. ABO blood group and the risk of cancer among middle-aged people in Taiwan. Asia Pac J Clin Oncol. 2015;11(4):31–6.CrossRef Hsiao LT, et al. ABO blood group and the risk of cancer among middle-aged people in Taiwan. Asia Pac J Clin Oncol. 2015;11(4):31–6.CrossRef
29.
Zurück zum Zitat Zhang BL, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(11):4643–50.CrossRefPubMed Zhang BL, et al. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(11):4643–50.CrossRefPubMed
31.
Zurück zum Zitat Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin (Barc). 1991;96(20):761–4. Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin (Barc). 1991;96(20):761–4.
32.
Zurück zum Zitat Torti RA. ABO blood groups and Rh. Antigens in patients with carcinoma of the breast. Med Times. 1963;91:1167–8.PubMed Torti RA. ABO blood groups and Rh. Antigens in patients with carcinoma of the breast. Med Times. 1963;91:1167–8.PubMed
33.
Zurück zum Zitat Rai S, et al. ABO blood group distribution in carcinoma of the breast. Indian J Cancer. 1970;7(2):135–9.PubMed Rai S, et al. ABO blood group distribution in carcinoma of the breast. Indian J Cancer. 1970;7(2):135–9.PubMed
34.
Zurück zum Zitat Newell GR, et al. ABO blood groups and cancer. J Natl Cancer Inst. 1974;52(5):1425–30.PubMed Newell GR, et al. ABO blood groups and cancer. J Natl Cancer Inst. 1974;52(5):1425–30.PubMed
35.
Zurück zum Zitat Munzarova M, et al. Course of breast cancer disease and ABO blood groups. Biomed Pharmacother. 1985;39(9–10):486–9.PubMed Munzarova M, et al. Course of breast cancer disease and ABO blood groups. Biomed Pharmacother. 1985;39(9–10):486–9.PubMed
36.
37.
Zurück zum Zitat Khalili H, et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomark Prev. 2011;20(5):1017–20.CrossRef Khalili H, et al. ABO blood group and risk of colorectal cancer. Cancer Epidemiol Biomark Prev. 2011;20(5):1017–20.CrossRef
40.
Zurück zum Zitat Teresa DB, et al. Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes. Tumour Biol. 2010;31(5):401–9.CrossRefPubMed Teresa DB, et al. Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes. Tumour Biol. 2010;31(5):401–9.CrossRefPubMed
41.
Zurück zum Zitat Klimant E, et al. Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. Clin Med Res. 2011;9(3–4):111–8.CrossRefPubMedPubMedCentral Klimant E, et al. Blood type, hormone receptor status, HER2/neu status, and survival in breast cancer: a retrospective study exploring relationships in a phenotypically well-defined cohort. Clin Med Res. 2011;9(3–4):111–8.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3(4):237–52.PubMed Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist. 1998;3(4):237–52.PubMed
43.
Zurück zum Zitat Holdsworth PJ, et al. Blood group as a prognostic indicator in breast cancer. Br Med J (Clin Res Ed). 1985;290(6469):671–3.CrossRef Holdsworth PJ, et al. Blood group as a prognostic indicator in breast cancer. Br Med J (Clin Res Ed). 1985;290(6469):671–3.CrossRef
44.
Zurück zum Zitat Marionneau S, Le Moullac-Vaidye B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology. 2002;12(12):851–6.CrossRefPubMed Marionneau S, Le Moullac-Vaidye B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiology. 2002;12(12):851–6.CrossRefPubMed
45.
Zurück zum Zitat Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMed Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–502.CrossRefPubMed
47.
49.
Zurück zum Zitat Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14(10):506–12.CrossRefPubMed Gearing AJ, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14(10):506–12.CrossRefPubMed
50.
Zurück zum Zitat Pare G, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6578 women. PLoS Genet. 2008;4(7):e1000118.CrossRefPubMedPubMedCentral Pare G, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6578 women. PLoS Genet. 2008;4(7):e1000118.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Barbalic M, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010;19(9):1863–72.CrossRefPubMedPubMedCentral Barbalic M, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet. 2010;19(9):1863–72.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Ruggeri ZM. Structure and function of von Willebrand factor: relationship to von Willebrand’s disease. Mayo Clin Proc. 1991;66(8):847–61.CrossRefPubMed Ruggeri ZM. Structure and function of von Willebrand factor: relationship to von Willebrand’s disease. Mayo Clin Proc. 1991;66(8):847–61.CrossRefPubMed
54.
Zurück zum Zitat Franchini M, et al. von Willebrand factor and cancer: a renewed interest. Thromb Res. 2013;131(4):290–2.CrossRefPubMed Franchini M, et al. von Willebrand factor and cancer: a renewed interest. Thromb Res. 2013;131(4):290–2.CrossRefPubMed
55.
Zurück zum Zitat Gill JC, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–5.PubMed Gill JC, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691–5.PubMed
Metadaten
Titel
ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women
verfasst von
S. Zouine
F. Marnissi
N. Otmani
M. Bennani Othmani
M. El Wafi
K. Kojok
Y. Zaid
N. Tahiri Jouti
N. Habti
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 7/2016
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0784-2

Weitere Artikel der Ausgabe 7/2016

Medical Oncology 7/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.